Corporate History

50 year trails of Nichi-Iko

Fortunately,Nichi-Iko marked 50th anniversary on July 15 , 2015.
In commemoration of it, we made the movie to get you to feel Nichi-Iko's trails until now and challenges to the future.

Full version 16 minutes
*


1965 Nihon Iyakuhin Kogyo Co., Ltd. established
1967 Completed the plant to produce pharmaceutical tablets and powder in Toyama City, followed by the completion of the plant to produce injection drugs.
1970 Completed Namerikawa Plant in Namerikawa City
1972 Completed Research Institute on Toyama Plant premises
1974 Completed Head Office Building in Sogawa, Toyama City
1980 Listed on Nagoya Stock Exchange, Second mp4
1981 Listed on Osaka Stock Exchange, Second mp4
1983 Completed new GLP-compliant Research Institute adjacent to Namerikawa Plant
1985 Established Tokyo Branch Office Building in Bunkyo Ward, Tokyo
1986 Completed Fukuno Plant (now Nanto) in Fukunomachi, Higashi Tonamigun, Toyama Prefecture
1987 Launched SEDAPAIN Injection as new proprietary drug, a central nervous system analgesic
1993 Launched CADEX, a drug to treat pressure ulcer and skin ulcer under foreign license was obtained
1994 LaucnchedUNICON Tablets, a drug to treat asthma diseases under foreign license
1995 Established Head Office Annex as the 30th anniversary of company's foundation
1996 Completed revised GMP-compliant injection plant in Yasuda, Namerikawa City
1997 Adopted new GPMSP-compliant corporate framework
1998 Adopted new GCP-compliant corporate framework
2000 Established MPS (Medical Practice Support) team at all business offices
2001 Made partially acquisition of OTC business from Japan Tobacco, Inc.
Launched FERRUM Capsules, slow-release iron preparation for oral use and synthetic penicillin PENGOOD as Branded Generic Drug.
2003 Completed Nichi-Iko Distribution Center in Namerikawa City
Launched FESIN Injection, iron preparation for I.V. use as Branded Generic Drug.
2004 Installed new sales support system in the Sales Division.
Acquired the sales operation right of Maruko Pharmaceutical Co., Ltd.
2005 Merged Nihon-Gallen Co., Ltd.
Acquired partially the stock of Maruko Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
Changed the company name to Nichi-Iko Co., Ltd.(the official registered name in English :Nichi-Iko Pharmaceutical Co., Ltd.)
Acquired partially the stock of Oriental Pharmaceutical Co., Ltd., who was subsequently the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
2006 Completed Pharmaceutical Development Center adjacent to Namerikawa Plant
Commenced the operation of Higashi-Nihon Distribution Center
Promoted to First mp4 of both Osaka Stock Exchange and Nagoya Stock Exchange
2007 Merged with Maruko Pharmaceutical Co., Ltd. to be the wholly owned subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
Dissolved Kobayashi Yakugaku Industry Co., Ltd., one of the subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.
2008 Merged and Aquired Teikoku Medix Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd.
2009 Maruko Pharmaceutical Co., Ltd., Oriental Pharmaceutical Co., Ltd., and Teikoku Medix Co., Ltd. were consolidated to create Nichi-iko Pharma Factory Co., Ltd.
Active Pharma Co., Ltd., a manufacturer of Apls for generics, was created as a joint venture company with Mitani Sangyo Co., Ltd.
2010 Remodeled flagship plant "Pentagon" in Namerikawa city, Toyama started full operation.
Established sanofi-aventis Nichi-Iko K.K. by joint capital investment with sanofi-aventis Group (Currently SANOFI)
Entered into Full Agency Agreement regarding marketing, sales, distribution and logistics in Hong Kong, Thailand and Malayshia with DKSH.
Entered into a capital and business alliance agreement with Aprogen Inc. for research and development of biosimilar products. Listed on the Tokyo Stock Exchange, First mp4.
2011 Establishment of Nichi-Iko Medical Practice Institute Co., Ltd.
Completed Global Development center, Honeycomb building. Delisting from Osaka Stock Exchange and Nagoya Stock Exchange
2012 Announced the 6th Medium term business plan "Pyramid"
Acquired Yakuhan Pharmaceutical Co., Ltd.
Merger consolidated subsidiary, Nichi-Iko Pharmaceutical Co., Ltd.
Tokyo office became another head quarter and Namerikawa Plant 1& 2 renamed Toyama Plant 1& 2.
2013 Completed 2nd flagship plant "Pyramid" in Namerikawa city.
Merged and Aquired Yakuhan Pharmaceutical Co., Ltd., to be wholly owned subisidiary of Nichi-iko Pharmaceutical Co., Ltd.
Established Nichi-Iko Bangkok Representative Office in Thailand
Entered into a business alliance with Biolab in Thailand
Entered into a basic agreement for business acquisition of Astellas Pharma Group, Fuji Plant
Entered into an agreement for capital alliance with Binex in Korea
Entered into a business alliance with Hanoi Pharma in Vietnam
Issued the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution)
2014 Established Nichi-Iko (Thailand) Co., Ltd. as a 100% owned local subsidiary in Thailand
Established NIXS Corporation as a 100% owned local subsidiary in USA
Launched Nichi-Iko Pharma Tech Co., Ltd. as a consolidated subsidiary
2015 Entered into a business alliance with Bangkok Lab and Cosmetic in Thailand
2016 Announced the 7th Medium term business plan "Obelisk"
Acquired all outstanding stocks of Sagent Pharmaceuticals, Inc.and made it a wholly owned subsidiary.
2017 Obtained Marketing Approval for infliximab BS for I.V.Infusion 100mg "Nichi-Iko"
Merger consolidated subsidiary, Nichi-Iko Pharma Tech Co., Ltd.
12/13/2017 Completion of the new formulation facility “Obelisk Building” construction at the site of the Toyama Plant 1.
01/15/2018 Business alliance agreement with Lloyd Laboratories Inc. and Innogen Pharmaceuticals Inc. (Philippines)
03/28/2018 Strategic alliance agreement with Eisai Co., Ltd.
07/09/2018 Business alliance with Sunward Pharmaceutical Pte Ltd. (Singapore)